Arctic Blue Beverages to launch their first oat-based RTD
Arctic Blue Beverages has launched Hang Oat Vanilla, their first oat-based ready-to-drink (RTD). The product is already on sale in Finland and will later this year be more widely available in Europe.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005604/en/
Arctic Blue Beverages has launched Hang Oat Vanilla, their first oat-based ready-to-drink (RTD). The product is already on sale in Finland and will later this year be more widely available in Europe. The novelty drink is based on the multi-award winning Arctic Blue Gin. “This new product expands our range of oat-based products. It is aimed especially at younger, conscious people, for whom sustainability is important, ”says Valtteri Eroma, CEO of Arctic Blue Beverages. (Photo: Business Wire)
The novelty drink is based on the multi-award winning Arctic Blue Gin. The oat-based drink combines the tastes of the wild northern nature and pure Finnish water. The drink is packed in Tetra Pak carton.
“This new product expands our range of oat-based products. It is aimed especially at younger, conscious people, for whom sustainability is important, ”says Valtteri Eroma, CEO of Arctic Blue Beverages.
Hang Oat Vanilla is Arctic Blue Beverages' first oat-based mild alcoholic beverage. In the future, the company intends to expand its RTD product range (ready-to-drink) by launching new flavors and packaging sizes both in Finland and abroad.
Eroma is pleased that Arctic Blue Beverages has the opportunity to respond to the rapidly growing trend of RTD beverages and the popularity of dairy-free oat products, and to develop new oat products.
“We have created an innovation platform that allows our product development to answer quickly to trends and market changes without taking months of development work, ”says Eroma.
According to Eroma, the market for RTD drinks has grown tremendously globally, and at the same time, oat-based options are taking up shelf space from traditional dairy products.
“Growth in both categories is immersive. With the new Hang Oat Vanilla just launched, we are among the first to take part in the growing segment, ”he says.
Arctic Blue Beverages Oy is a Finnish beverage company whose best-known products are the multi-award winning Arctic Blue Gin, Arctic Blue Gin Navy Strength and the world’s first dairy-free gin-based oat liqueur, Arctic Blue Oat. The company invests heavily in the export market and its products are sold in Japan, Australia and more than a dozen other countries globally.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
CEO & Head of Brand
+358 40 550 1343
PR- & communications Agency Mellakka Helsinki
+358 400 380010
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Global Student Innovation Challenge Calls on Next-Generation Leaders to Tackle Water Security5.3.2024 13:00:00 EET | Press release
Global water technology leader Xylem (NYSE: XYL) is inviting high school and university students worldwide to develop solutions to the world’s biggest water challenges by joining the 2024 Global Student Innovation Challenge. Innovators aged between 13-25 can submit ideas to tackle three global problems: reducing plastic ocean waste, lowering greenhouse gas (GHG) emissions, and minimizing water waste – all of which supports more secure and resilient water systems for communities. During the 8-week challenge, which begins on March 15, students will be mentored by leading water industry experts and learn about key water challenges and concepts. The top teams will share a $20,000 prize pool and can join the Xylem Ignite Innovation Incubator to further develop their solutions. The deadline for submissions is May 8, 2024. “We’re at an inflection point for water - with intensifying challenges, but also enormous opportunity to solve these issues through innovation," said Austin Alexander, Vice
Enosium Life Science, a New Integrated Scientific Services Group for Biopharma Companies in Europe5.3.2024 12:00:00 EET | Press release
Dr Antoine Amer, supported by Otium Capital, announced the creation of Enosium Life Science, a group poised to redefine services in the healthcare market by acquiring and combining best-in-class life science experts in Europe. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240305557434/en/ Enosium Life Science aims to be a key advisory and scientific services provider for pharmaceuticals, biotech and medtech firms from clinical development to commercialisation. Antoine Amer brings 20+ years of global pharmaceutical leadership experience in launching and growing healthcare innovations. A Multi-Specialist European Group Dedicated to Life Sciences Enosium Life Science combines local knowledge, scientific expertise, entrepreneurial agility, and international standards to address critical challenges facing pharmaceutical companies. Enosium Life Science will implement a targeted acquisition strategy, focusing on service providers
Epsilogen and Lonza Announce Successful Large-Scale GMP Manufacturing of MOv18, an IgE Antibody Targeting Ovarian Cancer5.3.2024 11:02:00 EET | Press release
Epsilogen, a global leader in the development of immunoglobulin E (IgE) antibodies to treat cancer, and Lonza, a global development and manufacturing partner to the pharma, biotech and nutrition industries, today announced successful completion of Good Manufacturing Practice (“GMP”) manufacturing of MOv18 IgE, Epsilogen’s lead IgE antibody drug candidate. This included process development and cGMP manufacturing of this complex molecule for clinical supply in less than ten months at Lonza’s Slough (UK) site. IgE antibodies represent powerful alternatives to more commonly used IgG antibodies. They bring exciting opportunities for oncology thanks to their strong potency, long tissue half-life, and the ability to target tumour cells expressing very low antigen levels. Current research and monitoring indicate that this is the first time GMP manufacturing of a therapeutic IgE antibody has been completed at scale. Epsilogen intends to use this new material for its upcoming Phase Ib study in p
Manhattan Unveils First Unified Commerce Benchmark for Specialty Retail in Europe5.3.2024 11:00:00 EET | Press release
Manhattan Associates Inc. (NASDAQ: MANH) today announced the findings of the industry's first real-world analysis of Unified Commerce in specialty retail in Europe conducted in partnership with Google Cloud and Zebra Technologies. The Unified Commerce Benchmark for Specialty Retail, conducted by Incisiv via actual shopping transactions, assessed three retail verticals (apparel and footwear, home and DIY, and luxury), and five countries (France, Germany, Italy, UK, and the Netherlands). The Unified Commerce Benchmark for Specialty Retail in Europe conducted by Incisiv, assessed 50 retailers, analysing 290+ customer experience capabilities in four categories including: search and discovery; cart and checkout; promising and fulfilment and service and support. Based on data from actual purchases, returns and customer journeys across digital and physical channels, the benchmarking reveals common attributes of successful retailers and opportunities for retailers to improve customer value and
Fujirebio Europe Expands Its Portfolio With Introduction of the Innovative PreCursor-M AnoGYN assay (RUO) for Methylation Testing in Anal Specimens5.3.2024 09:00:00 EET | Press release
Fujirebio Europe and Self-screen B.V. today announced an expansion of their commercial collaboration with the distribution of the PreCursor-M AnoGYN methylation-specific molecular assay from Self-screen B.V. The test is intended for the detection of promoter hypermethylation of the genes ASCL1 and ZNF582 and is used to test the methylations status of anal specimens for research use only (RUO). It complements Fujirebio's HPV-associated molecular test portfolio. “The Human Papilloma Virus (HPV) test panel of Fujirebio Europe continues to grow with effective and accurate testing solutions, and we are pleased to add this new RUO methylation-based assay to our molecular testing toolbox,” says Christiaan De Wilde, CEO at Fujirebio Europe “With its unmatched accuracy and reliability, this innovative PreCursor-M AnoGYN assay represents a significant advancement for research studies in the field of anal cancer prevention. We wanted our customers to have access to this valuable research tool as
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom